GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GT Biopharma (NASDAQ: GTBP) announced that Michael Breen, Executive Chairman and CEO, will participate in the Centurion One Capital 3rd Annual Bahamas Summit at the Rosewood Baha Mar Hotel in Nassau, Bahamas on October 28–29, 2025.
The company said it will be available for one-on-one investor meetings during the conference and invited interested parties to contact their Centurion One Capital representative to schedule meetings.
GT Biopharma (NASDAQ: GTBP) ha annunciato che Michael Breen, Presidente esecutivo e CEO, parteciperà al Centurion One Capital 3rd Annual Bahamas Summit presso l'hotel Rosewood Baha Mar a Nassau, Bahamas, il 28–29 ottobre 2025.
L'azienda ha comunicato che sarà disponibile per incontri individuali con investitori durante la conferenza e ha invitato le parti interessate a contattare il proprio rappresentante Centurion One Capital per fissare gli incontri.
GT Biopharma (NASDAQ: GTBP) anunció que Michael Breen, Presidente Ejecutivo y CEO, participará en la Centurion One Capital 3rd Annual Bahamas Summit en el Rosewood Baha Mar Hotel en Nassau, Bahamas, los 28–29 de octubre de 2025.
La compañía indicó que estará disponible para reuniones individuales con inversionistas durante la conferencia e invitó a las partes interesadas a ponerse en contacto con su representante de Centurion One Capital para programar las reuniones.
GT Biopharma (NASDAQ: GTBP)는 Michael Breen, Executive Chairman 및 CEO가 Centurion One Capital 제3회 연례 바하마 정상회의에 Nassau, Bahamas의 Rosewood Baha Mar 호텔에서 2025년 10월 28–29일에 참가할 것이라고 발표했습니다.
회사는 컨퍼런스 기간 동안 투자자 일대일 미팅이 가능하다고 밝히고, 미팅 일정을 잡으려면 Centurion One Capital 대표에게 연락해 달라고 초대했습니다.
GT Biopharma (NASDAQ: GTBP) a annoncé que Michael Breen, Président exécutif et PDG, participera au Centurion One Capital 3rd Annual Bahamas Summit à l'hôtel Rosewood Baha Mar à Nassau, Bahamas, les 28–29 octobre 2025.
La société a indiqué qu'elle serait disponible pour des entretiens individuels avec les investisseurs lors de la conférence et a invité les parties intéressées à contacter leur représentant Centurion One Capital pour programmer les rencontres.
GT Biopharma (NASDAQ: GTBP) gab bekannt, dass Michael Breen, Executive Chairman und CEO, am Centurion One Capital 3rd Annual Bahamas Summit im Rosewood Baha Mar Hotel in Nassau, Bahamas, am 28.–29. Oktober 2025 teilnehmen wird.
Das Unternehmen teilte mit, dass es während der Konferenz für Einzelgespräche mit Investoren zur Verfügung stehen wird und interessierte Parteien aufgefordert wurden, sich an ihren Centurion One Capital-Vertreter zu wenden, um Meetings zu vereinbaren.
GT Biopharma (NASDAQ: GTBP) أعلنت أن مايكل بريين، رئيس المجلس التنفيذي والرئيس التنفيذي، سيشارك في قمة Centurion One Capital السنوية الثالثة في جزر البهاما في فندق Rosewood Baha Mar بناباو، البهاما، في 28–29 أكتوبر 2025.
قالت الشركة إنها ستكون متاحة لعقد اجتماعات فردية مع المستثمرين خلال المؤتمر ودعت الأطراف المهتمة للاتصال بممثل Centurion One Capital لديهم لترتيب الاجتماعات.
GT Biopharma (NASDAQ: GTBP) 宣布，执行董事长兼首席执行官迈克尔·布林将参加在巴哈马拿骚Rosewood Baha Mar Hotel举行的 Centurion One Capital 第3届 Bahamas 峰会，时间为2025年10月28–29日。
公司表示，在会议期间将提供一对一投资者会谈，并邀请有意者联系他们的 Centurion One Capital 代表安排会谈。
- None.
- None.
SAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 3rd Annual Bahamas Summit at the Rosewood Baha Mar Hotel from Tuesday, October 28th to Wednesday, October 29th, 2025, in Nassau, Bahamas.
The Company will be available for one-on-one meetings at the conference. If interested, please contact your Centurion One Capital representative.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
FAQ
When will GT Biopharma (GTBP) participate in the Centurion One Capital Bahamas Summit?
Who from GT Biopharma will attend the October 2025 Bahamas Summit?
Can investors meet GT Biopharma management at the Centurion One Capital summit?
What is GT Biopharma's stock symbol and is it mentioned for the event?
Where is the Centurion One Capital 3rd Annual Bahamas Summit being held?
